Tolga Tanguler is Executive Vice President and Chief Commercial Officer at Alnylam Pharmaceuticals, where he plays a pivotal role in transforming the company into a fully integrated biotech specializing in RNAi therapeutics, a groundbreaking class of medicines. He has over 20 years of experience in the global biopharmaceutical industry, having led commercialization efforts from early development to product launch and growth management across a broad range of therapeutic areas. Prior to Alnylam, Tolga served as Head of U.S. at Alexion, launching three new products, and achieving over $3 billion in revenue. Tolga spent most of his formative years at Pfizer, where he established and led the North America rare disease unit as its president, spearheading the company’s gene therapy innovation efforts.